Rare Genetic Diseases Archives · BioBuzz

Loading …

AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/04/Catalentcombo-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/04/Catalentcombo-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/04/Catalentcombo-75x75.jpg 75w" data-src="https://biobuzz.io/wp-content/uploads/2021/04/Catalentcombo-300x300.jpg" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/04/Catalentcombo-300x300.jpg" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/04/Catalentcombo-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/04/Catalentcombo-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/04/Catalentcombo-75x75.jpg 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : April 27, 2021April 27, 2021 Published by : BioBuzz Media

Partnership to advance AavantiBio’s diversified gene therapy pipeline, including the Company’s lead program in Friedreich’s Ataxia (FA)